Use

The FR? protein is expressed in 90% of ovarian cancers and has limited expression in normal tissue, making it an attractive therapeutic target. In using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay for the evaluation of ovarian cancer patients, approximately 35% of patients are considered to have high expression of FR?—as defined by the scoring criteria mentioned above— and thus eligible for treatment with ELAHERE™.